Semaglutide belongs to the drug class known as glucagon-like peptide-1 (GLP-1) receptor agonists
Resmetirom provides significant low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (ApoB) reduction along with early hepatic antifibrotic effects, whereas semaglutide leads to substantial weight loss and wide-ranging cardiometabolic improvements
This medication mimics the incretin hormone produced by the intestines, encouraging insulin secretion in response to meals while also inhibiting glucagon release
The same gastrointestinal side effects, central adaptations, and pleiotropic actions that once discouraged development are now recognized as manageable features of peptide pharmacology when appropriately contextualized
Both numbers reflect the 12-month bundle commitment, and the ads use starting at or for as low as framing without disclosing the commitment up front
The 10mg mixing chart provides visual references for these concentrations